SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare jumps as its arm gets CEP from EDQM for Ursodeoxycholic Acid API

01 Aug 2024 Evaluate

Shilpa Medicare is currently trading at Rs. 694.25, up by 12.15 points or 1.78% from its previous closing of Rs. 682.10 on the BSE.

The scrip opened at Rs. 682.10 and has touched a high and low of Rs. 739.90 and Rs. 682.10 respectively. So far 68254 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 739.90 on 1-Aug-2024 and a 52 week low of Rs. 296.45 on 26-Oct-2023.

Last one week high and low of the scrip stood at Rs. 739.90 and Rs. 660.00 respectively. The current market cap of the company is Rs. 6790.11 crore.

The promoters holding in the company stood at 44.39%, while Institutions and Non-Institutions held 16.69% and 38.92% respectively.

Shilpa Medicare’s subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Ursodeoxycholic Acid.

Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used to dissolve cholesterol gall stones and to treat cholestatic forms of liver diseases including primary biliary cirrhosis. Ursodiol has been linked to rare instances of transient and mild serum aminotransferase elevations during therapy and to rare instances of jaundice and worsening of liver disease in patients with preexisting cirrhosis.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications. 

Shilpa Medicare Share Price

455.65 19.40 (4.45%)
11-May-2026 12:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1873.30
Dr. Reddys Lab 1293.35
Cipla 1317.60
Zydus Lifesciences 943.10
Lupin 2252.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×